Shares of Tandem Diabetes Care Inc (NASDAQ:TNDM) gapped up before the market opened on Monday after Oppenheimer raised their price target on the stock from $80.00 to $84.00. The stock had previously closed at $63.52, but opened at $65.26. Tandem Diabetes Care shares last traded at $62.61, with a volume of 33,828 shares traded.
Several other research firms also recently weighed in on TNDM. Leerink Swann began coverage on Tandem Diabetes Care in a research note on Monday, May 13th. They set an “outperform” rating and a $83.00 price target on the stock. Craig Hallum reiterated a “buy” rating and set a $84.00 price target (up previously from $70.00) on shares of Tandem Diabetes Care in a research note on Wednesday, May 1st. Svb Leerink began coverage on Tandem Diabetes Care in a research note on Monday, May 13th. They set an “outperform” rating and a $83.00 price target on the stock. UBS Group boosted their price target on Tandem Diabetes Care from $53.00 to $66.00 and gave the company a “neutral” rating in a research note on Tuesday, April 30th. Finally, Stifel Nicolaus boosted their price target on Tandem Diabetes Care from $58.00 to $70.00 and gave the company a “hold” rating in a research note on Wednesday, May 1st. Four research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $68.38.
In other news, Director Douglas A. Roeder sold 35,688 shares of the company’s stock in a transaction dated Thursday, June 13th. The stock was sold at an average price of $70.07, for a total value of $2,500,658.16. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Leigh Vosseller sold 10,000 shares of the company’s stock in a transaction dated Thursday, May 16th. The stock was sold at an average price of $70.45, for a total value of $704,500.00. Following the completion of the sale, the chief financial officer now owns 12,009 shares in the company, valued at approximately $846,034.05. The disclosure for this sale can be found here. In the last quarter, insiders have sold 76,066 shares of company stock worth $5,315,927. Company insiders own 6.90% of the company’s stock.
The company has a current ratio of 2.43, a quick ratio of 2.13 and a debt-to-equity ratio of 0.09. The company has a market cap of $3.64 billion, a PE ratio of -25.21 and a beta of 0.33. The firm has a 50 day moving average price of $64.11.
Tandem Diabetes Care (NASDAQ:TNDM) last issued its earnings results on Thursday, August 1st. The medical device company reported ($0.03) EPS for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.20. Tandem Diabetes Care had a negative return on equity of 20.21% and a negative net margin of 19.55%. The firm had revenue of $93.26 million for the quarter, compared to the consensus estimate of $69.95 million. During the same quarter in the prior year, the business earned ($0.33) earnings per share. The company’s revenue was up 173.2% compared to the same quarter last year. As a group, equities analysts predict that Tandem Diabetes Care Inc will post -0.81 EPS for the current year.
Tandem Diabetes Care Company Profile (NASDAQ:TNDM)
Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.
Featured Article: Net Margin – Understanding the Different Kinds of Profit
Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.